Tratamiento de la mielofibrosis idiopática crónica con bajas dosis de talidomida. Comunicación de 2 casos

Ávila Cabrera, Onel M; Espinosa Martínez, Edgardo; Hernández Padrón, Carlos; Izquierdo Cano, Lisset; Ramón Rodríguez, Luis G; Espinosa Estrada, Edgardo.
Rev. cuba. hematol. inmunol. hemoter ; 26(2): 57-61, Mayo-ago. 2010.
Artículo en Español | LILACS | ID: lil-584688

Documentos relacionados

  1. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
  2. Long-term outcome of pomalidomide therapy in myelofibrosis.
  3. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
  4. Defining disease modification in myelofibrosis in the era of targeted therapy.
  5. [Assessing lenalidomide for treating multiple myeloma, myelofibrosis and myelodysplastic syndrome].
  6. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
  7. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
  8. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
  9. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
  10. The role of therapy in the outcome of patients with myelofibrosis.